RPL11

Across TCGA pan-cancer cohorts, RPL11 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated RPL11 data layer compared with 25 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher RPL11 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated RPL11 expression acts as an unfavorable survival marker, although some lineages such as LUAD and HNSC show a favorable association.

CCRCC, LUAD, and GBM are the cancer types where RPL11 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Median	All	0.739	0.947	.003	46	view →
LUAD	DFS	Tertile	III,IV	1.000	0.405	.005	13	view →
GBM	DFS	Quartile	All	0.211	0.451	.012	11	view →
PDAC	OS	Median	II,III,IV	0.719	0.925	.035	3	view →
HNSC	DFS	Quartile	II,III,IV	0.926	0.719	.040	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

RPL11–CCRCC (OS)

Open the CCRCC breakdown →